FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) > Cancer Cell

Cancer Cell

Cancer Cell patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/28/14 - 20140242095 - Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
The invention relates to modulating the SIRPα—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRPα antibodies and antibody fragments, preferably used for treating hematological cancer....

08/07/14 - 20140220043 - Gene signature for predicting prognosis of patients with solid tumors
Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression...

07/31/14 - 20140212439 - Anti-epha2 antibody
The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1...

07/17/14 - 20140199330 - Protein involved in detection of cancer metastasis and a treatment thereof
Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues. TRPV4...

07/10/14 - 20140193432 - Anti-hdlk-1 antibody having an antitumor activity in vivo
The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent,...

07/10/14 - 20140193433 - Bcma-based stratification and therapy for multiple myeloma patients
The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA...

07/10/14 - 20140193434 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which...

07/03/14 - 20140186374 - Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells...

07/03/14 - 20140186375 - Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection....

07/03/14 - 20140186376 - Compositions and methods for inhibiting ccl3
The present invention relates to the discovery that CCL3, through at least one of its receptors CCR1 and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include,...

06/26/14 - 20140178409 - Sema5b peptides and vaccines including the same
As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and...

06/12/14 - 20140161825 - Methods of treating acute myeloid leukemia by blocking cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc....

06/12/14 - 20140161826 - Non-self t-cell epitope fused to an antibody that recognises a tumour-specific cell-surface receptor and uses thereof
A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the...

06/05/14 - 20140154268 - Alpha5-beta1 antibodies and their uses
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided....

06/05/14 - 20140154269 - Targeted nanovectors and their use for treatment of brain tumors
In some embodiments, the invention pertains to therapeutic compositions for treating a brain tumor. Such therapeutic compositions generally comprise: (1) a nanovector; (2) an active agent associated with the nanovector with activity against brain tumor cells; and (3) a targeting agent associated with the nanovector with recognition activity for a...

05/08/14 - 20140127237 - Anti-mesothelin antibodies
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well...

05/08/14 - 20140127238 - Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network...

05/01/14 - 20140120116 - Treatment of cancer using smad3 inhibitor
The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of...

05/01/14 - 20140120117 - Treatment of tumors using specific anti-l1 antibody
The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment....

04/17/14 - 20140105916 - Human c-fms antigen binding proteins
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages....

04/17/14 - 20140105917 - Frizzled-binding agents and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using...

04/17/14 - 20140105918 - Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate...

04/17/14 - 20140105919 - Synergistic inhibition of erbb2/erbb3 signal pathways in the treatment of cancer
Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling....

04/10/14 - 20140099332 - Diagnostic assays and kits for detection of folate receptor 1
The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided....

04/03/14 - 20140093521 - Therapeutic dll4 binding proteins
Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or...

03/27/14 - 20140086938 - Methods of inhibiting tumor growth using ttk antagonists
The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like...

03/27/14 - 20140086939 - Compositions and methods for detecting and treating cancer
The invention provides methods for detecting the presence of cancer initiating cells in a tissue, methods for identifying test agent for reducing cancer, and methods for reducing cancer in a subject. The invention's methods are applicable to any cancer, and in particular to liver cancer. The invention also provides the...

03/27/14 - 20140086940 - Herceptin® adjuvant therapy
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®....

03/20/14 - 20140079720 - Inhibitors of extracellular hsp90
The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion...

02/27/14 - 20140056921 - Hepatocyte growth factor receptor antagonists and uses thereof
Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,...

02/27/14 - 20140056922 - Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune...

02/13/14 - 20140044739 - Cdim binding proteins and uses thereof
The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin...

02/13/14 - 20140044740 - Diagnostic and therapeutic targets for leukemia
The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity....

02/13/14 - 20140044741 - B-type plexin antagonists and uses thereof
The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying...

02/06/14 - 20140037655 - Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors...

01/30/14 - 20140030276 - Cancer immunopotentiating agent containing rankl antagonist
The present invention provides a cancer immunopotentiating agent containing a compound that blocks RANKL action. The present invention relates to a cancer immunopotentiating agent containing a RANKL antagonist such as an anti-RANKL neutralizing antibody as an active ingredient....

12/26/13 - 20130344093 - Anti-egfr antibodies and uses thereof
The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth...

12/12/13 - 20130330362 - Humanized anti-egfr antibody l4-h3 and coding gene thereof
A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is...

11/28/13 - 20130315934 - Methods and compositions for assessing and treating cancer
The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based...

11/21/13 - 20130309253 - Cancer treatment with endothelin receptor antagonists
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are...

11/21/13 - 20130309254 - Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
Described herein is the identification of 68 genes with an elevated frequency of somatic mutations in melanoma. Nine genes were identified that exhibited recurring mutations in melanoma. The TRRAP gene was mutated at nucleotide 2165 (C2165T) in six different melanoma tumor samples. In addition, 16 genes were identified that were...

11/21/13 - 20130309255 - Biomarkers, uses of biomarkers and a method of identifying biomarkers
The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin, protein tenascin, protein periostin, protein galectin, protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl transferase 2, protein agrin, protein adipocyte enhancer-binding...

11/14/13 - 20130302355 - Novel modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided....

11/14/13 - 20130302356 - Method of treating cancer with dll4 antagonist and chemotherapeutic agent
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of...

11/07/13 - 20130295118 - Antibodies specific for cll-1
Provided herein are antibodies specific for CLL-1....

11/07/13 - 20130295119 - Folate receptor 1 antibodies and immunoconjugates and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided....

10/31/13 - 20130287798 - Uses of monoclonial antibody 8h9
This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light...

10/24/13 - 20130280277 - Notch1 receptor binding agents and methods of use thereof
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand...

10/24/13 - 20130280278 - Anti-vegfr-3 antibody compositions
The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease....

10/17/13 - 20130273079 - Ultraconserved regions encoding ncrnas
Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs....

10/10/13 - 20130266592 - Companion animal treatments
The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy....

10/10/13 - 20130266593 - Microvesicle protein for cancer targeting
Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binging agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment....

10/10/13 - 20130266594 - Anti-notch1 antibodies
The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions....